Nathalie K. Zgheib_PHRM240_Chemotherapy_MCQs_Key.docx

**Nathalie K. Zgheib\_PHRM240\_Chemotherapy\_MCQs\_Key** 1. **Obstacles to successful chemotherapy include:** a. High growth fraction b. Non-solid tumors c. High Karnofsky performance scale d. Large tumor 2. **The following is recommended for successful chemotherapy:**...

**Nathalie K. Zgheib\_PHRM240\_Chemotherapy\_MCQs\_Key** 1. **Obstacles to successful chemotherapy include:** a. High growth fraction b. Non-solid tumors c. High Karnofsky performance scale d. Large tumor 2. **The following is recommended for successful chemotherapy:** e. Stop treatment cycles when the cancer is no more detectable by PET scan f. Decrease the chemotherapeutic drug doses in consecutive cycles g. Optimize dosing schedules h. Combine chemotherapeutic drugs that have the same mechanism of action 3. **Cell cycle phase non specific drugs:** i. Do not act on resting cells j. Can be given as a single bolus k. Should be given as a prolonged infusion l. Are schedule dependent drugs 4. **Glucocorticoids may be used in cancer treatment because:** m. They suppress nausea and vomiting n. They increase cerebral edema secondary to irradiation o. The promote weight loss p. They increase the neutrophils count 5. **Which of the below strategies to achieve maximum benefit from cytotoxic chemotherapy is set up depending on whether the drug is cell cycle phase specific or not?** q. Regional drug delivery r. Intermittent chemotherapy s. Combination chemotherapy t. Optimizing dosing schedule 6. **Gastrointestinal cells are more prone to toxicity from cytotoxic drugs when compared to brain cells because they:** u. Are more numerous v. Are disseminated in the body w. Have a higher growth fraction x. Have more time for repair 7. **Mechanisms of cytotoxic drug resistance include all [EXCEPT]:** y. Reduced cytotoxic drug intake z. Reduced cytotoxic drug efflux a. Reduced cytotoxic drug activation b. Reduced target molecule sensitivity 8. **Barriers of cancer therapy include the fact that:** c. At any given dose, a cytotoxic drug kills a constant number of cancer cells d. Cancer cells are like normal cells e. Cytotoxic drugs boost immunity f. Normal cells repopulate more slowly than cancer cells 9. **Combining cytotoxic drugs that have no overlapping toxicity is potentially associated with:** g. More drug resistance h. Better response rates i. More injury to normal cells j. Higher relapse rates 10. **Nausea and vomiting is a very common adverse effect of cytotoxic drugs. It:** k. Results from a direct inhibition of the chemoreceptor trigger zone l. Occurs 7-10 days after treatment, and persists for 1-2 months after the last treatment m. Can be managed with steroids premedication n. Is associated with hyperuricemia and kidney injury 11. **Some hormonal agents can be used to treat cancer. But these are not called cytotoxic drugs because:** o. They are not effective p. They are not associated with toxicity q. They are all administered PO r. They do not disrupt the cell cycle 12. **The mechanism of action of tamoxifen is the following:** s. It blocks HER 2 receptors in the breast tissue t. It inhibits estrogen synthesis from androgenic precursors u. It blocks estrogen receptors in the breast v. It blocks EGFR receptors in the breast 13. **A patient with brain cancer asks the nurse why they are putting the drug into her back instead of a vein. The nurse's response should be that:** w. the drug cannot be administered intravenously x. this route allows higher doses of chemotherapy to be used y. the drug can better reach the tumor cells z. this route prevents formation of drug-resistant mutations in the cancer cells 14. **A patient receiving chemotherapy develops hyperuricemia. A nursing priority addresses the effect of the urate crystals on the:** a. Blood b. Joints c. Kidneys d. liver 15. **When teaching a patient who is receiving a cytotoxic drug, the nurse explains that the greatest danger of contracting an infection caused by the effect of the drug on the immune system usually occurs:** e. The day before the next scheduled infusion f. 10 to 14 days after the infusion g. 24 to 48 hours after the infusion h. During the infusion 16. **You order vincristine, the prototype of the vinca alkaloids, to a patient with a tumor that is likely to be responsive to this drug. What is the most likely adverse response to this drug?** a. Nephrotoxicity, renal dysfunction or failure b. Neutropenia c. Peripheral sensory and motor neuropathy d. Pulmonary damage 17. **A cancer patient develops severe, irreversible cardiomyopathy because the maximum lifetime dose of an anticancer drug was exceeded. What drug was most likely responsible for this?** a. Cisplatin b. Cyclophosphamide c. Doxorubicin d. Vincristine 18. **A patient with Wilms tumor is receiving a chemotherapeutic agent that is described as working by intercalating into DNA strands, and that is efficacious regardless of which stage of the cell cycle the tumor cells are in. Which drug best fits this description?** a. Mwethotrexate b. Doxorubicin c. Fluorouracil d. Tamoxifen 19. **A 30-year-old woman being treated for ovarian cancer develops high frequency hearing loss and declining renal function in response to anticancer drug therapy. Which drug is the most likely cause?** a. Bleomycin b. Cisplatin c. Doxorubicin d. Fluorouracil 20. **A 41-year-old woman comes to the outpatient area of the hematology-oncology center for her first course of adjuvant chemotherapy for metastatic breast cancer following a left modified radical mastectomy and axillary lymph node dissection for infiltrating ductal carcinoma of the breast. Two biopsies were positive for cancer. Following premedication with dexamethasone and ondansetron, she will receive combination chemotherapy with doxorubicin, cyclophosphamide, and fluorouracil. Twenty-four hours after the first course of chemotherapy she will start a 10-day regimen with a G-CSF. What is the most likely reason for administering the G-CSF?** a. Control of nausea and emesis b. Potentiate the anticancer effects of the chemotherapeutic agents c. Reduce the risk/severity of chemo-induced neutropenia, and related infections d. Stimulate the gastric mucosa to repair damage cause by the chemotherapy drugs